Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Proof of Principle Program - Phase I

University of Toronto

$159,904.00

High Quality Sperm Selection for Assisted Reproductive Technology

FY 2014-15

Summary
QSpermTM is a one-step, inexpensive, easy-to-use microfluidic solution that uses state-of-the-art knowledge of sperm swimming behaviour to select high quality sperm to improve the success rate of assisted reproduction. In preliminary testing the alpha prototype has shown an 80% improvement in human DNA integrity, significantly outperforming current practices. Our preliminary market research has indicated great potential for such a technology in assisted reproductive technology (ART), which encompasses in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) performed by fertility specialists. However, critical technical refinements are required as well as rigorous clinical validation testing. The targeted research and proof-of-concept testing proposed here are essential to engaging early-stage customers and downstream investment.
Program
Proof of Principle Program - Phase I
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
315087
Name
Sinton David A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Human Development, Child and Youth Health
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
High Quality Sperm Selection for Assisted Reproductive Technology
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$159,904
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Aneuploidy; Assisted Reproductive Technology (Art); Dna Integrity; Microfluidics; Morphology; Motility; Semen Preparation; Sperm Selectiom
Abstract
QSpermTM is a one-step, inexpensive, easy-to-use microfluidic solution that uses state-of-the-art knowledge of sperm swimming behaviour to select high quality sperm to improve the success rate of assisted reproduction. In preliminary testing the alpha prototype has shown an 80% improvement in human DNA integrity, significantly outperforming current practices. Our preliminary market research has indicated great potential for such a technology in assisted reproductive technology (ART), which encompasses in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) performed by fertility specialists. However, critical technical refinements are required as well as rigorous clinical validation testing. The targeted research and proof-of-concept testing proposed here are essential to engaging early-stage customers and downstream investment.
Competitiondate
201409
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sinton, David A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $159,904~ $0~
University of Toronto - $159,904 Grant (2014-15) | Canada Spends